佐力药业(300181) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 495.70 million, an increase of 12.81% compared to CNY 439.42 million in the same period last year[4]. - Net profit attributable to shareholders for Q1 2023 was CNY 97.45 million, representing a growth of 41.76% from CNY 68.75 million year-on-year[4]. - Total operating revenue for Q1 2023 reached ¥495,697,829.83, an increase of 12.8% compared to ¥439,416,764.79 in Q1 2022[23]. - Net profit for Q1 2023 was ¥99,453,357.42, representing a 36.6% increase from ¥72,755,387.42 in Q1 2022[24]. - Total comprehensive income for the period was CNY 51,254,457.45, compared to a loss of CNY 139,671,939.61 in the previous period[25]. - Basic and diluted earnings per share increased to CNY 0.1389 from CNY 0.1130 year-over-year[25]. Cash Flow and Liquidity - The net cash flow from operating activities decreased by 85.99% to CNY 12.01 million, down from CNY 85.73 million in the previous year[4]. - Cash inflow from operating activities was CNY 529,472,730.86, up from CNY 439,531,004.52 in the previous period[26]. - Net cash flow from operating activities decreased to CNY 12,013,227.66 from CNY 85,732,512.56 year-over-year[26]. - Cash outflow from investing activities totaled CNY 75,105,495.75, compared to CNY 183,996,549.20 in the previous period[28]. - Net cash flow from investing activities was negative CNY 64,248,767.61, an improvement from negative CNY 120,739,205.69 year-over-year[28]. - Cash inflow from financing activities was CNY 78,000,000.00, down from CNY 177,572,000.00 in the previous period[28]. - The ending balance of cash and cash equivalents was CNY 1,009,262,229.22, compared to CNY 183,024,828.55 in the previous period[28]. - The company reported cash and cash equivalents of CNY 1,022,965,970.70 at the end of Q1 2023, down from CNY 1,082,070,763.05 at the beginning of the year[19]. Research and Development - R&D expenses for Q1 2023 amounted to CNY 18.21 million, a significant increase of 56.11% compared to CNY 11.57 million in the same period last year[9]. - Research and development expenses increased to ¥18,208,988.62 in Q1 2023, compared to ¥11,664,510.89 in Q1 2022, marking a growth of 55.9%[23]. Assets and Liabilities - The total assets at the end of Q1 2023 were CNY 3.60 billion, a slight decrease of 1.16% from CNY 3.64 billion at the end of the previous year[4]. - Total liabilities decreased to ¥785,641,351.46 in Q1 2023 from ¥879,192,754.90 in Q1 2022, a reduction of 10.6%[21]. - The company's equity attributable to shareholders increased by 1.96% to CNY 2.76 billion compared to CNY 2.70 billion at the end of the previous year[4]. - The equity attributable to shareholders of the parent company rose to ¥2,756,618,357.18 in Q1 2023, up from ¥2,703,749,664.26 in Q1 2022[21]. Inventory and Costs - The company reported a gross profit margin decrease due to increased costs, with operating costs rising by 21.37% to CNY 149.29 million[9]. - The company experienced a significant increase in inventory, which rose by 16.34% to CNY 370.92 million, primarily due to anticipated price increases in traditional Chinese medicine materials[8]. - Inventory increased to CNY 370,920,557.09 from CNY 318,826,460.84, reflecting a growth of approximately 16.3%[19]. - Total operating costs for Q1 2023 were ¥400,185,140.69, up from ¥371,390,609.52 in the same period last year, reflecting a rise of 7.3%[23]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,698[12]. - The largest shareholder, Yu Youqiang, holds 18.52% of shares, totaling 129,890,463 shares, with 97,417,847 shares pledged[12]. - The top ten shareholders include both individual and institutional investors, with UBS AG holding 1.40% of shares[13]. - The total number of preferred shareholders is zero, indicating no preferred shares outstanding[14]. - The company has not disclosed any related party transactions among the top ten shareholders[13]. Future Plans - The company plans to continue investing in long-term assets, including the "Intelligent Traditional Chinese Medicine Production Base Construction and Upgrade Project"[8]. - The company plans to continue focusing on market expansion and new product development to drive future growth[24]. Audit and Reporting - The company did not undergo an audit for the first quarter report[29]. - The report was released by the board of directors on April 24, 2023[30].